AVNS Avanos Medical, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AVNS Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$13.09
52W High
$17.69
52W Low
$9.3
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$607.62M
P/E
N/A
ROE
-46.7%
Profit margin
-67.0%
Debt/Equity
0.17
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with a -67% profit margin and negative ROE of -46.68%, undermining valuation appeal. While revenue growth is positive at 4.3% YoY and recent earnings surprises have been strong, the lack of sustained profitability, deteriorating insider sentiment, and poor long-term price performance (-72.6% over 5 years) raise serious concerns. The absence of Altman Z-Score and key financial data limits confidence, but current signals point to a distressed or speculative investment.
Key Strengths
Revenue growth of 4.3% YoY shows top-line resilience in a challenging sector environment
Gross margin of 52.28% indicates strong pricing power and cost control at the production level
Low valuation multiples: P/B of 0.78 and P/S of 0.87 suggest potential undervaluation relative to book and sales
Current ratio of 2.38 reflects solid short-term liquidity and ability to meet obligations
Recent quarterly earnings have beaten estimates 3 out of the last 4 quarters with high average surprise of 47%
Key Risks
Piotroski F-Score of 2/9 signals severe financial weakness, particularly in profitability and leverage metrics
Profit margin of -67% and ROE of -46.68% indicate deep unprofitability and inefficient use of equity
Missing Altman Z-Score prevents definitive distress assessment, but negative earnings and ROE imply high bankruptcy risk
Insider selling activity: 1 sale worth $0.17M with no buys in the last 6 months signals lack of confidence from management
Long-term price performance is deeply negative: -72.6% over 5 years, indicating persistent value destruction
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
65
45
30
20
0
AI Verdict
High-risk speculative position with weak fundamentals despite some valuation appeal
Key drivers: Low Piotroski F-Score (2/9), Negative profitability metrics, Recent insider selling, Strong gross margins and revenue growth, Deep undervaluation on P/B and P/S
Confidence
70%
Value
65/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.78 suggests stock trades below tangible asset value
- Price/Sales of 0.87 is low for medical devices sector
Watchpoints
- P/E and PEG unavailable due to unprofitability
- Graham Number unavailable — no defensive fair value can be calculated
Future
45/100
Ref Growth rates
Positives
- 4.3% YoY revenue growth indicates modest top-line momentum
- Forward P/E of 13.78 implies reasonable earnings expectations if profitability returns
Watchpoints
- No YoY earnings growth data available
- Recent EPS growth shows volatility: +29.4% Q/Q but -38.9% YoY
Past
30/100
Ref Historical trends
Positives
- Quarterly earnings have beaten estimates in 3 of last 4 quarters
- Historical earnings surprises were strong, including +230% and +110% in 2020
Watchpoints
- 5-year price return of -72.6% shows severe underperformance
- Multiple earnings misses in recent years, including -25.8% surprise in Q3 2023
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity ratio of 0.17 indicates low leverage
- Current ratio of 2.38 and quick ratio of 1.23 show adequate liquidity
Watchpoints
- Piotroski F-Score of 2/9 indicates critical financial weakness
- ROE of -46.68% and negative profit margin signal severe profitability issues
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength score of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$13.09
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AVNS and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AVNS
Avanos Medical, Inc.
Primary
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
+15.4% | +15.4% | +8.4% | +98.8% | +19.4% | +26.4% |
|
BBNX
Beta Bionics, Inc.
Peer
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
|
BCYC
Bicycle Therapeutics plc
Peer
|
-74.2% | -74.7% | -47.5% | -20.1% | -0.6% | +6.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
13.78
PEG Ratio
N/A
P/B Ratio
0.78
P/S Ratio
0.87
EV/Revenue
0.96
EV/EBITDA
9.0
Market Cap
$607.62M
Profitability
Profit margins and return metrics
Profit Margin
-67.0%
Operating Margin
0.28%
Gross Margin
52.28%
ROE
-46.68%
ROA
1.58%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.17
Low debt
Current Ratio
2.38
Strong
Quick Ratio
1.23
Good
Cash/Share
$1.52
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-02
$N/A
2025-11-05
$0.22
+83.3% surprise
2025-08-05
$0.17
+13.3% surprise
2025-05-06
$0.26
+44.4% surprise
Healthcare Sector Comparison
Comparing AVNS against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-46.68%
This Stock
vs
-52.77%
Sector Avg
-11.5%
(Below Avg)
Profit Margin
-67.0%
This Stock
vs
-20.78%
Sector Avg
+222.5%
(Superior)
Debt to Equity
0.17
This Stock
vs
6.16
Sector Avg
-97.2%
(Less Debt)
Revenue Growth
4.3%
This Stock
vs
137.39%
Sector Avg
-96.9%
(Slower)
Current Ratio
2.38
This Stock
vs
3.36
Sector Avg
-29.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $627.4M | - | -2698.5% | -% | $6.46 | |
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | |
|
BCYC
Bicycle Therapeutics plc
|
BEARISH | $482.11M | - | -34.6% | -% | $6.95 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-18 | HOLBROOK KERR | Officer | Sale | 15,000 | $165,014 |
| 2025-08-13 | BLACKFORD GARY D | Director | Purchase | 60,000 | $659,300 |
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning AVNS from our newsroom.
Newest → oldest
No matching news yet.